Pradžia › Amiloidozė › Merilendas
Amiloidozė klinikiniai tyrimai Merilendas
7 tyrimai dėl Amiloidozė ieško dalyvių vietose Merilendas.
Miestai Merilendas
Oficialus tyrimo tekstas (anglų kalba)
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
- Research Site, Baltimore
Renkami dalyviaiStebimasis tyrimas
Amžius nuo 18 iki 130 · Visoms lytims · Atnaujinta 2026-09-23 · NCT06465810TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
- Clinical Trial Site, Baltimore
Renkami dalyviai3 fazė
Amžius nuo 18 iki 85 · Visoms lytims · Atnaujinta 2026-09-16 · NCT07052903TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
- Clinical Trial Site, Baltimore
Renkami dalyviai3 fazė
Amžius nuo 18 iki 85 · Visoms lytims · Atnaujinta 2026-09-15 · NCT07223203ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
- Clinical Trial Site, Baltimore
Renkami dalyviaiStebimasis tyrimas
Visi amžiai · Visoms lytims · Atnaujinta 2026-09-08 · NCT04561518Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
- University of Maryland Medical Center, Baltimore
- Johns Hopkins University, Baltimore
Renkami dalyviai3 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-08-04 · NCT06563895Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid Load
- National Institutes of Health Clinical Center, Bethesda
Renkami dalyviai1 fazė
Amžius nuo 18 iki 120 · Visoms lytims · Atnaujinta 2026-05-19 · NCT06974877MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
- Johns Hopkins University, Baltimore
Renkami dalyviai3 fazė
Amžius nuo 18 iki 90 · Visoms lytims · Atnaujinta 2026-03-27 · NCT06128629Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.